Food & Function,
Journal Year:
2023,
Volume and Issue:
14(18), P. 8309 - 8320
Published: Jan. 1, 2023
Astaxanthin
is
a
naturally
occurring
compound
that
possesses
immunomodulatory
properties.
The
results
of
our
previous
investigation
indicated
astaxanthin
has
the
potential
to
augment
anticancer
effectiveness
targeted
medication
sorafenib.
However,
precise
molecular
mechanism
underlying
this
phenomenon
remains
unclear.
H22
tumor-bearing
mice
were
treated
with
sorafenib
at
30
mg
kg-1
per
day
and
their
diet
was
supplemented
60
day-1
orally
for
period
18
days.
study
revealed
addition
facilitated
transition
tumor-associated
macrophages
from
M2
phenotype
M1
phenotype.
application
resulted
in
an
augmentation
CD8+
T
cell
infiltration
within
tumor
microenvironment
through
activation
CXCL9/CXCR3
signaling
axis.
found
enhance
production
cytokines
possess
antitumor
properties,
including
Granzyme
B.
Furthermore,
administration
alterations
intestinal
microbiota
H22-bearing
mice,
leading
growth
bacteria
anti-tumor
immune
such
as
Akkermansia.
findings
these
studies
indicate
response
against
tumors
when
used
conjunction
These
offer
novel
framework
advancement
agent
dietary
supplement
individuals
tumors.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: April 29, 2024
Abstract
Hepatocellular
carcinoma
(HCC)
is
a
major
health
concern
worldwide,
with
limited
therapeutic
options
and
poor
prognosis.
In
recent
years,
immunotherapies
such
as
immune
checkpoint
inhibitors
(ICIs)
have
made
great
progress
in
the
systemic
treatment
of
HCC.
The
combination
treatments
based
on
ICIs
been
trend
this
area.
Recently,
dual
blockade
durvalumab
plus
tremelimumab
has
also
emerged
an
effective
for
advanced
However,
majority
HCC
patients
obtain
benefits.
Understanding
immunological
rationale
exploring
novel
ways
to
improve
efficacy
immunotherapy
drawn
much
attention.
review,
we
summarize
latest
area,
ongoing
clinical
trials
immune-based
therapies,
well
strategies
chimeric
antigen
receptor
T
cells,
personalized
neoantigen
vaccines,
oncolytic
viruses,
bispecific
antibodies.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(24), P. 6025 - 6025
Published: Dec. 7, 2022
Cancer
is
the
second
leading
cause
of
death
in
world
and
seriously
affects
quality
life
patients.
The
diagnostic
techniques
for
tumors
mainly
include
tumor
biomarker
detection,
instrumental
examination,
tissue
biopsy.
In
recent
years,
liquid
technology
represented
by
circulating
DNA
(ctDNA)
has
gradually
replaced
traditional
with
its
advantages
being
non-invasive
accurate,
high
specificity,
sensitivity.
ctDNA
may
carry
throughout
circulatory
system
through
cell
necrosis,
apoptosis,
exosome
secretion,
etc.,
carrying
characteristic
changes
tumors,
such
as
mutation,
methylation,
microsatellite
instability,
gene
rearrangement,
etc.
this
paper,
mutation
objects
to
describe
preparation
process
before
analysis,
detection
methods
two
gene-level
changes,
including
a
series
enrichment
derived
from
PCR,
sequencing-based
techniques,
comprehensive
are
combined
new
materials.
addition,
role
various
stages
cancer
development
summarized,
early
screening,
diagnosis,
molecular
typing,
prognosis
prediction,
recurrence
monitoring,
drug
guidance.
summary,
an
ideal
involved
whole
development.
Cancer Research and Treatment,
Journal Year:
2023,
Volume and Issue:
55(2), P. 351 - 366
Published: March 14, 2023
Circulating
tumor
DNA
(ctDNA)
is
the
portion
of
cell-free
in
blood
cancer
patients
released
from
cells
via
apoptosis,
necrosis,
or
active
release.
From
10
mL
blood,
4-5
plasma
obtained
a
patient
contains
5-10
ng/mL
ctDNA.
The
not
only
ctDNA
origin,
but
also
normal
clonal
hematopoiesis.
Another
characteristic
its
rapid
clearance
circulation;
it
has
half-life
16
minutes
to
2.5
hours.
Obtaining
reliable
results
requires
application
and
approval
standardized
clinical
validation
guidelines;
however,
status
numerous
tests
currently
varies.
use
testing
should
be
carefully
considered
based
on
test's
specific
needs
characteristics.
Here
we
provide
different
characteristics
information
regarding
their
status.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Aug. 14, 2023
In
this
multicenter,
single-arm
phase
2
trial
(ChiCTR1900024428),
patients
with
locally
advanced
gastric/gastroesophageal
junction
cancers
receive
one
cycle
of
sintilimab
(anti-PD1)
and
chemotherapy
(S-1
nab-paclitaxel),
followed
by
5
weeks
concurrent
chemoradiotherapy
sintilimab,
another
thereafter.
Surgery
is
preferably
scheduled
within
to
three
weeks,
cycles
adjuvant
are
administrated.
The
primary
endpoint
the
pathological
complete
response.
Our
results
meet
pre-specified
endpoint.
Thirteen
34
(38.2%)
enrolled
achieve
response
(95%
CI:
22.2-56.4).
secondary
objectives
include
disease-free
survival
(DFS),
major
response,
R0
resection
rate,
overall
(OS),
event-free
(EFS),
safety
profile.
median
DFS
EFS
were
17.0
(95%CI:
11.1-20.9)
21.1
14.7-26.1)
months,
respectively,
while
OS
was
not
reached,
1-year
rate
92.6%
50.1-99.5%).
Seventeen
(50.0%)
have
grade
≥3
adverse
events
during
preoperative
therapy.
prespecified
exploratory
biomarker
analysis,
CD3
Molecular Biomedicine,
Journal Year:
2024,
Volume and Issue:
5(1)
Published: May 31, 2024
Abstract
Liver
cancer
remains
one
of
the
most
prevalent
malignancies
worldwide
with
high
incidence
and
mortality
rates.
Due
to
its
subtle
onset,
liver
is
commonly
diagnosed
at
a
late
stage
when
surgical
interventions
are
no
longer
feasible.
This
situation
highlights
critical
role
systemic
treatments,
including
targeted
therapies,
in
bettering
patient
outcomes.
Despite
numerous
studies
on
mechanisms
underlying
cancer,
tyrosine
kinase
inhibitors
(TKIs)
only
widely
used
clinical
inhibitors,
represented
by
sorafenib,
whose
application
greatly
limited
phenomenon
drug
resistance.
Here
we
show
an
in-depth
discussion
signaling
pathways
frequently
implicated
pathogenesis
targeting
these
under
investigation
or
already
use
management
advanced
cancer.
We
elucidate
oncogenic
roles
especially
hepatocellular
carcinoma
(HCC),
as
well
current
state
research
respectively.
Given
that
TKIs
represent
sole
class
therapeutics
for
employed
practice,
have
particularly
focused
encountered
phenomena
resistance
during
HCC
treatment.
necessitates
imperative
development
innovative
strategies
urgency
overcoming
existing
limitations.
review
endeavors
shed
light
utilization
therapy
vision
improve
unsatisfactory
prognostic
outlook
those
patients.
